Preparation of aminoglycoside-loaded chitosan nanoparticles using dextran sulphate as a counterion

被引:53
作者
Lu, Enxian [2 ]
Franzblau, Scott [3 ]
Onyuksel, Hayat [2 ]
Popescu, Carmen [1 ,2 ,3 ]
机构
[1] DeCode Genet, Woodrige, IL 60517 USA
[2] Univ Illinois, Dept Biopharmaceut Sci, Chicago, IL USA
[3] Univ Illinois, Inst TB Res, Chicago, IL USA
关键词
Aminoglycoside; oral delivery; chitosan; nanoparticle; streptomycin; gentamicin; tobramycin; MURINE TUBERCULOSIS; ORAL-DRUG; DELIVERY; VACCINATION; MOUSE;
D O I
10.1080/02652040802365182
中图分类号
O69 [应用化学];
学科分类号
081704 ;
摘要
Purpose. To prepare aminoglycoside (AG) (streptomycin, gentamicin and tobramycin) loaded chitosan nanoparticles with high drug incorporation efficiency and test the in vivo oral efficacy of streptomycin (SM) loaded chitosan nanoparticles in a Mycobacterium tuberculosis (TB) chronic infection mouse model. Method. Dextran sulphate (a polyanion) was used to shield the positive charge of AG and increase the drug incorporation in the chitosan nanoparticle. By varying the concentration of each component, the formulation of SM-loaded chitosan nanoparticle was optimized by monitoring the drug incorporation efficacy and particle size. The mechanism of the nanoparticle formation was suggested and the preparation method was applied to two other aminoglycosides (AG): gentamicin (GM) and tobramycin (TM). The resulting nanoparticles were characterized by particle diameter, drug incorporation efficacy, drug loading efficacy and zeta potential. The in vitro drug release from these nanoparticles was carried out in pH 1.2 and pH 7.4 buffer. Preliminary in vivo oral efficacy studies of SM-loaded chitosan nanoparticles was performed in a Mycobacterium tuberculosis (TB) chronic infection mouse model. Results. The optimal concentration of streptomycin (SM)/dextran sulphate/chitosan/tripolyphosphate (TPP) for SM nanoparticles preparation was 2/1.2/2/0.8 mg mL(-1). Through calculation, the optimal concentrations of dextran sulphate are 2.5 mg mL(-1)and 2.4 mg mL(-1) for 2mg mL(-1) gentamicin and tobramycin, respectively (Table 1). The resulting AG chitosan nanoparticles had a high drug incorporation efficacy with particle sizes in the nanometre range. The in vitro drug release studies showed that more than 60% drug is retained inside the nanoparticles in pH 1.2 buffer after 6 h. The preliminary in vivo results indicated that oral SM chitosan nanoparticles induced one log 10 reduction (p<0.01) in growth of the bacilli and were as effective as subcutaneously injected aqueous SM solution at the same concentration (100 mg kg(-1)). Conclusion. Dextran sulphate can significantly increase AG incorporation into the chitosan nanoparticles. The concentration of each component was critical in preparing AG-loaded chitosan nanoparticles. The chitosan nanoparticles designed in this study may provide a promising oral drug delivery formulation for AG which usually, in tuberculosis treatment, is administrated as an injectible preparation.
引用
收藏
页码:346 / 354
页数:9
相关论文
共 24 条
[1]   Effective treatment of acute and chronic murine tuberculosis with liposome-encapsulated clofazimine [J].
Adams, LB ;
Sinha, I ;
Franzblau, SG ;
Krahenbuhl, JL ;
Mehta, RT .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (07) :1638-1643
[2]   Formation of new glucomannan-chitosan nanoparticles and study of their ability to associate and deliver proteins [J].
Alonso-Sande, Maria ;
Cuna, Margarita ;
Remunan-Lopez, Carmen .
MACROMOLECULES, 2006, 39 (12) :4152-4158
[3]   N-Trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination:: Biological properties and immunogenicity in a mouse model [J].
Amidi, Maryam ;
Romeijn, Stefan G. ;
Verhoef, J. Coos ;
Junginger, Hans E. ;
Bungener, Laura ;
Huckriede, Anke ;
Crommelin, Daan J. A. ;
Jiskoot, Wim .
VACCINE, 2007, 25 (01) :144-153
[4]   Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis [J].
Baldwin, SL ;
D'Souza, C ;
Roberts, AD ;
Kelly, BP ;
Frank, AA ;
Lui, MA ;
Ulmer, JB ;
Huygen, K ;
McMurray, DM ;
Orme, IM .
INFECTION AND IMMUNITY, 1998, 66 (06) :2951-2959
[5]   Use of microsphere technology for targeted delivery of rifampin to Mycobacterium tuberculosis-infected macrophages [J].
Barrow, ELW ;
Winchester, GA ;
Staas, JK ;
Quenelle, DC ;
Barrow, WW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (10) :2682-2689
[6]   Chitosan nanoparticles for oral drug and gene delivery [J].
Bowman, Katherine ;
Leong, Kam W. .
INTERNATIONAL JOURNAL OF NANOMEDICINE, 2006, 1 (02) :117-128
[7]   Oral particulate delivery: status and future trends [J].
Chen, HM ;
Langer, R .
ADVANCED DRUG DELIVERY REVIEWS, 1998, 34 (2-3) :339-350
[8]   The activity of low-clearance liposomal amikacin in experimental murine tuberculosis [J].
Dhillon, J ;
Fielding, R ;
Adler-Moore, J ;
Goodall, RL ;
Mitchison, D .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 (06) :869-876
[9]  
DUBEY RR, 2003, AAPS PHARMSCITECH, V5, P1
[10]   The aminoglycosides [J].
Edson, RS ;
Terrell, CL .
MAYO CLINIC PROCEEDINGS, 1999, 74 (05) :519-528